Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 9/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355641 | 0.87 | JAK3 (0.42) | PIK3CBPIK3CAJAK3HTT | |
| SCHEMBL6500066 | 0.84 | JAK3 (0.41) | KMT2AMEN1POLBJAK3ELANE | |
| SCHEMBL4524341 | 0.81 | HTR3E (0.49) | HTT | |
| SCHEMBL5413458 | 0.78 | PIK3CA (0.50) | PIK3CAPIK3R1KMT2AMEN1POLB | |
| SCHEMBL22576043 | 0.77 | TP53 (0.45) | PIK3CBPIK3CAPIK3R1KMT2AMEN1 | |
| SCHEMBL30828738 | 0.74 | JAK3 (0.59) | PIK3CAPIK3R1JAK3GAASMN1; SMN2 | |
| SCHEMBL6066498 | 0.74 | ROCK2 (0.38) | JAK3HTT | |
| SCHEMBL29760694 | 0.73 | SMN1; SMN2 (0.40) | PIK3CBPIK3CAPIK3R1JAK3ELANE | |
| SCHEMBL31434956 | 0.73 | JAK3 (0.44) | PIK3CAPIK3R1KMT2AMEN1POLB | |
| SCHEMBL16835984 | 0.72 | PIK3CA (0.48) | PIK3CAPIK3R1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| CN-107721937-B | Preparation method and application of compound containing pyrimidone skeleton | 沈阳药科大学 | 2021-02-05 | — | — | CN | disclosed |
| CN-104603113-B | Novel 2, 3-dihydro-1H-imidazo {1,2-a } pyrimidin-5-one and 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives comprising substituted morpholines, preparation thereof and pharmaceutical use thereof | 赛诺菲 | 2020-01-21 | — | — | CN | disclosed |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2019-09-26 | — | — | US | disclosed |
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2019-04-09 | — | — | US | disclosed |
| EP-2448939-B1 | 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THE PREPARATION AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| CN-102548970-B | Novel (6-oxo-1, 6-dihydropyrimidin-2-yl) amide derivatives, process for their preparation and their medical use as akt (pkb) phosphorylation inhibitors | SAI NUOFEI (FR) | 2015-11-25 | — | — | CN | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| CN-102482286-B | Novel 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives, their preparation and their medical use | SANOFI SA | 2015-07-15 | — | — | CN | disclosed |
| CN-102482285-A | Novel 2, 3-dihydro-1H-imidazo {1,2-a } pyrimidin-5-one derivatives, their preparation and their pharmaceutical use | SANOFI AVENTIS | 2012-05-30 | — | — | CN | disclosed |
| CN-102482286-A | Novel 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives, their preparation and their medical use | SANOFI SA | 2012-05-30 | — | — | CN | disclosed |
| EP-2448939-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| EP-2448932-A1 | NOVEL 6-MORPHOLIN-4-YL-PYRIMIDIN-4-(3H)-ONE DERIVATIVES, AND THE PHARMACEUTICAL PREPARATION THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| EP-2448940-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| EP-2448927-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001114-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001113-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001112-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001115-A1 | NOVEL 6-MORPHOLIN-4-YL-PYRIMIDIN-4-(3H)-ONE DERIVATIVES, AND THE PHARMACEUTICAL PREPARATION THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | MTX1, RDX, MTX2 | PIK3CB 4600/4885PIK3CA 3685/4885PIK3R1 2536/4885 |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | CBR3, MTX1, CBR1 | PIK3CB 4637/4885PIK3CA 3644/4885PIK3R1 2358/4885 |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | CCNY, CBR3, CBR1 | PIK3CB 4621/4885PIK3CA 3887/4885PIK3R1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.